New High Stocks: APO, ADB, BRK.B, LLY, MA
Hi, tigers! Welcome to our “New High Stocks“ Column! Let’s check out the winners that continue to post strong performance and reach to new high in recent period.
1. $Apollo Global Management LLC(APO)$ rose to new high of $88.88 on 6th Sept.
Back in August, Apollo Global Management began its rally after a strong Q2 earnings report. The stock broke out of a bullish pattern, hitting a 52-week high.
This year, it has gained over 32%. Q2 revenue reached $13.7 billion, with significant growth in retirement services and net investment income.
Analysts predict continued EPS growth for the company. Full-year EPS will grow to $6.57, vs. a loss of $3.89 in 2022, then increase to $7.81 next year.
2. $Adobe(ADBE)$ rose to $569.98 on 5th Sept.
SaaS stocks have been performing well recently. As we mentioned earlier, SaaS companies are well-positioned to shape the evolution of the tech industry by integrating Generative AI into their product roadmaps.
Adobe is one of the strongest performers in AI-concepts. Adobe offered a bundled solution of its products named Adobe Creative Suite, which evolved into a subscription software as a service (SaaS) offering named Adobe Creative Cloud.
3. $Berkshire Hathaway(BRK.B)$ rose to an all-time-high of $366.47, surpassing the former high in March 2022.
Berkshire Hathaway sold $13 billion in stocks in the second quarter and bought less than $5 billion, resulting in a net sale of $8 billion in stock. This move is seen as a strategy to bolster cash reserves in preparation for a potential recession.
Buffett's cautious approach and the strong performance of $Berkshire Hathaway(BRK.B)$ may indicate a lack of confidence in the stock market, and investors are closely monitoring his next moves.
4. $Eli Lilly(LLY)$ rose to an all time high of $561.93 on 6th Sept.
Eli Lilly is making rapid progress in the field of weight loss.
Its weight loss drugs - Tirzepatide's sales reached $1.55 billion, with second-quarter sales hitting $980 million. Lilly has also raised its annual sales projection for Tirzepatide to $4 billion.
This impressive financial report has shown investors a highly promising path in the weight loss field.
5. $MasterCard(MA)$ rose to $417.78 on 31st Aug.
Mastercard exceeded expectations in its recent quarterly earnings report.
The company reported EPS of $2.89, beating analyst estimates by $0.05. Second-quarter revenue totaled $6.30 billion, surpassing expectations. Mastercard achieved an impressive net margin of 43.37% and a remarkable return on equity of 178.10%.
Mastercard is positioned for growth due to robust consumer spending in travel, an expanded service lineup, increased cross-border transactions, and global expansion.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.